News

Be The Cure Research Story: Deborah McLeod’s Experience as a Participant in the VICTORIA trial

A new research story on BeTheCure.ca highlights Deborah McLeod’s experience as a participant in the VICTORIA trial, and the important discoveries that have been made about vericiguat and its impact on patients with heart failure. To learn more about Deborah’s story and the vital role patient participation has in clinical research, view the blog post here: bethecure.ca/stories/deborah/

Read Article



Canadian Cardiac Chronicle – Fall 2020 Issue

We are pleased to share with you the Fall 2020 edition of the Canadian Cardiac Chronicle. Along with our current trial updates and feature publications, the following items are highlighted in this issue: A letter from CVC co-director Dr. Shaun Goodman examining what the pandemic has taught us about clinical research The 2019 CVC annual report […]

Read Article



2019 CVC Annual Report

We are pleased to share the 2019 CVC annual report. This year’s theme, A Decade of Discovery, celebrates the pathway forged by the CVC over the past ten years. Our staff and faculty have all made important contributions to this compendium. We hope you enjoy reading more about who we are and what we do […]

Read Article


Canadian Cardiac Chronicle – Spring 2020 Issue

We are pleased to share with you the spring 2020 edition of the Canadian Cardiac Chronicle. Along with our current trial updates and feature publications, the following items are highlighted in this issue: A letter from CVC Co-Director Dr. Justin Ezekowitz reflecting upon adapting to the current challenging events, celebrating accomplishments, and continuing to remain creative […]

Read Article


New Study Findings: Treating Heart Attacks with Clot Busting Drugs Leads to Better Health Outcomes

Dr. Kevin Bainey, Director of the CVC ECG Core Laboratory, was featured on multiple news outlets discussing key results from the recent publication Pharmacoinvasive Strategy Versus Primary Percutaneous Coronary Intervention in ST-Elevation Myocardial Infarction in Clinical Practice: Insights From the Vital Heart Response Registry. This publication was also coauthored by several other members of the […]

Read Article



Vericiguat Meets Primary Endpoint in the VICTORIA Study

On November 18th it was announced that the Phase 3 VICTORIA study evaluating the efficacy and safety of vericiguat, a soluble guanylate cyclase (sGC) stimulator being developed to treat patients with worsening chronic heart failure, has met the primary efficacy endpoint. Vericiguat reduced the risk of the composite endpoint of heart failure hospitalization or cardiovascular […]

Read Article